Table 4.

Correlations¹ between changes in high-density lipoprotein (HDL) function and inflammation markers after agraz consumption, compared to placebo, in women with metabolic syndrome.

Changes in Variables	IL-1β (pg/mL)	IL-6 (pg/mL)	IL-8 (pg/mL)	MCP-1 (pg/mL)	TNF-α (pg/mL)
Apo A1 (mg/dL)	0.151	0,022	0.056	−0.087	0.030
PON1 Arylesterase Activity (kU/L)	0.215	−0.273	−0.106	−0.060	−0.012
PON1 Lactonase Activity (kU/L)	0.060	−0.390*	−0.169	0.145	−0.213
MPO (ng/mL)	0.102	0.707 ***	0.338	0.413 *	0.196
MPO/PON1 arylesterase ratio	0.097	0.682 ***	0.349	0.393 *	0.229
MPO/PON1 lactonase ratio	0.099	0.701 ***	0.323	0.295	0.202
AOPP (µM)	0.098	0.080	−0.228	0.170	−0.087
Cholesterol efflux (%)	−0.594 ***	−0.283	−0.128	−0.148	−0.496 **

¹ Pearson and Spearman correlation coefficients. Significance at * p < 0.05, ** p < 0.01, *** p < 0.001. Apo, apolipoprotein; PON1, paraoxonase 1; MPO, myeloperoxidase; AOPP, advanced oxidation protein products; TNF-α, tumor necrosis factor-alpha; IL, interleukin; MCP-1, monocyte chemoattractant protein-1.